Analyst Price Targets — PRQR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 14, 2024 5:02 am | Keay Nakae | Loop Capital Markets | $2.50 | $2.32 | StreetInsider | ProQR Therapeutics N.V. (PRQR) PT Raised to $2.50 at Chardan Capital Markets |
| December 30, 2022 2:09 am | Raymond James Raymond James | Raymond James | $5.00 | $3.37 | Pulse 2.0 | ProQR Therapeutics (PRQR) Stock Gets A $5 Price Target |
| December 22, 2022 9:59 am | Jennifer Kim | Cantor Fitzgerald | $5.00 | $2.70 | StreetInsider | Cantor Fitzgerald Upgrades ProQR Therapeutics N.V. (PRQR) to Overweight |
| August 12, 2022 5:08 am | Keay Nakae | Chardan Capital | $2.00 | $0.82 | TheFly | ProQR Therapeutics downgraded to Neutral from Buy at Chardan |
Latest News for PRQR
ProQR Therapeutics (NASDAQ: PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA editing program AX-0810, a next-generation follow-on candidate (AX-0811), and the addition of two programs, AX-0422 for Hurler syndrome and AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH). AX-0810:…
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its virtual Investor and Analyst event hosted today.
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ ProQR establishes AI Advisory Board with leaders from industry and academia ProQR's first AI-discovered Development Candidate expected to enter the clinic in 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRQR.
U.S. House Trading
No House trades found for PRQR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.